Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Interleukin 37 containing drug, preparation method and application thereof

A technology for interleukins and drugs, which is applied in the directions of preparation methods of interleukins and peptides, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2014-10-08
SHENZHEN UNIV
View PDF4 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] At present, there have been some studies on the anti-inflammatory effect of IL-37, but no relevant research has clearly revealed its effect on RA, SLE, AD, CD, psoriasis, MS, asthma, diabetes, TR, atherosclerosis, IBD , AS, hyperthyroidism, HT and AA diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interleukin 37 containing drug, preparation method and application thereof
  • Interleukin 37 containing drug, preparation method and application thereof
  • Interleukin 37 containing drug, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0137] The preparation method of the medicine of the present invention can be that the active ingredient of the present invention (interleukin-37, its derivatives, variants and / or truncated polypeptides, or their coding sequences) is properly mixed with the above-mentioned pharmaceutically acceptable carrier obtain pharmaceutical preparations. Methods for the preparation of pharmaceutical formulations are well known to those skilled in the art.

[0138] 5. The medicine taking method and preparation form of the present invention

[0139] The medicine prepared by the method provided by the invention can be taken orally (oral) or parenterally (also known as parenteral). The parenteral administration methods include local, joint cavity, arterial, intramuscular, subcutaneous, intraosseous, intracapsular, intraventricular, intravenous, intraperitoneal, mucosal or nasal injection and other methods.

[0140] Oral pharmaceutical compositions can be prepared in appropriate oral doses ...

Embodiment 1

[0187] Example 1: Extraction and Identification of Bovine Type II Collagen

[0188] (1) Extraction of bovine type II collagen

[0189] 1) Grinding: Take fresh bovine cartilage, remove the periosteum, cut into thin slices, and freeze and grind in liquid nitrogen (the more finely ground the cartilage is, the more uniform it will be, and the higher the yield of bovine type II collagen will be).

[0190] 2) Digestion with guanidine hydrochloride: suspend 10 times the volume of 4M guanidine hydrochloride, stir at 4°C for 24 hours, centrifuge at 5000 rpm for 20 minutes, discard the supernatant, and collect the precipitate (guanidine hydrochloride can remove a large amount of polysaccharide protein in cartilage).

[0191] 3) Pepsin digestion: After the precipitate was fully washed with 0.5M Tris-HCl and 0.5M acetic acid, it was suspended with 5 times the volume of pepsin digestion solution, stirred at 4°C for 48h, centrifuged at 5000rpm for 30min, and the supernatant was collected an...

Embodiment 2

[0198] Embodiment 2: the establishment of RA animal model

[0199] (1) Preparation of collagen emulsion

[0200] Add a certain amount of bovine type II collagen to 0.1M glacial acetic acid solution with a concentration of 2.5mg / ml, and emulsify overnight in a refrigerator at 4°C; mix the emulsified collagen with an equal volume of Freund’s complete tubercle bacillus on ice The adjuvant CFA makes it emulsify completely to obtain collagen emulsion. The standard of complete emulsification: dripping on water does not spread; generally, it needs to be emulsified for at least 2 hours. If the drop spreads on water, it should continue to emulsify.

[0201] (2) Immune sensitization

[0202] Take 8- to 10-week-old male experimental mice and keep them in an SPF-grade animal room at 24°C±2°C with a 12-hour light / dark cycle.

[0203] Immunization of DBA mice: After DBA mice were anesthetized, each mouse was subcutaneously injected with a total of 100 μl of collagen emulsion at the tail....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an interleukin in pharmacy, and in particular discloses interleukin 37 (IL-37) as an active ingredient of a drug and preparation thereof. At the same time, the invention discloses IL-37, its derivative, variant and / or truncated polypeptide as the active ingredient, or coding nucleotide sequences of the substances as the active ingredients, discloses a method for expression and purification of IL-37 and its active ingredients by prokaryotic, eukaryotic and mammalian cells, and discloses cloning of the coding nucleotide sequences of the IL-37 and its active ingredients to various expression vectors to conduct gene therapy. The invention also discloses application of the active ingredients in treatment of autoimmunity or chronic non-infectious inflammatory diseases. The drug provided by the invention can be used for treatment of rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, psoriasis, Crohn's disease, multiple sclerosis, asthma, diabetes, transplant rejection, atherosclerosis or inflammatory bowel disease, etc.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to the application of interleukin-37 in pharmacy, in particular to the application of interleukin-37 and its biologically active fragments in the preparation of medicines for treating autoimmune or chronic non-infectious inflammatory diseases. Background technique [0002] Autoimmune diseases are caused by the body's inappropriate immune response to substances and tissues that normally exist in the body. The root cause of chronic non-infectious inflammatory diseases is the persistence of inflammatory factors and tissue damage. The inflammatory factors trigger various immune responses. reactions and autoimmune reactions. Cytokines mediate various immune responses and play a key role in the pathogenesis of various human autoimmune diseases and chronic non-infectious inflammatory diseases, mainly including rheumatoid arthritis, systemic lupus erythematosus, specific Atopic dermatitis, Crohn's ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/20C12N15/70C07K14/54C07K1/22A61P37/02A61P29/00A61P19/02A61P17/00A61P17/06A61P1/00A61P11/06A61P3/10A61P37/06A61P9/10A61P19/00A61P7/06A61P7/00A61P5/16
Inventor 黄钟叶亮温中阳肖淑英李小青
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com